GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDL BioPharma Inc (NAS:PDLI) » Definitions » Inventory Turnover

PDL BioPharma (PDL BioPharma) Inventory Turnover : 0.23 (As of Jun. 2020)


View and export this data going back to 1992. Start your Free Trial

What is PDL BioPharma Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. PDL BioPharma's Cost of Goods Sold for the three months ended in Jun. 2020 was $2.64 Mil. PDL BioPharma's Average Total Inventories for the quarter that ended in Jun. 2020 was $11.59 Mil. PDL BioPharma's Inventory Turnover for the quarter that ended in Jun. 2020 was 0.23.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. PDL BioPharma's Days Inventory for the three months ended in Jun. 2020 was 400.67.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. PDL BioPharma's Inventory-to-Revenue for the quarter that ended in Jun. 2020 was 2.22.


PDL BioPharma Inventory Turnover Historical Data

The historical data trend for PDL BioPharma's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PDL BioPharma Inventory Turnover Chart

PDL BioPharma Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Inventory Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 1.41 5.08 3.45 1.83

PDL BioPharma Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.31 0.81 0.44 0.11 0.23

PDL BioPharma Inventory Turnover Calculation

PDL BioPharma's Inventory Turnover for the fiscal year that ended in Dec. 2019 is calculated as

Inventory Turnover (A: Dec. 2019 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Dec. 2019 ) / ((Total Inventories (A: Dec. 2018 ) + Total Inventories (A: Dec. 2019 )) / count )
=53.619 / ((18.942 + 39.773) / 2 )
=53.619 / 29.3575
=1.83

PDL BioPharma's Inventory Turnover for the quarter that ended in Jun. 2020 is calculated as

Inventory Turnover (Q: Jun. 2020 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Jun. 2020 ) / ((Total Inventories (Q: Mar. 2020 ) + Total Inventories (Q: Jun. 2020 )) / count )
=2.639 / ((10.542 + 12.633) / 2 )
=2.639 / 11.5875
=0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PDL BioPharma  (NAS:PDLI) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

PDL BioPharma's Days Inventory for the three months ended in Jun. 2020 is calculated as:

Days Inventory =Average Total Inventories (Q: Jun. 2020 )/Cost of Goods Sold (Q: Jun. 2020 )*Days in Period
=11.5875/2.639*365 / 4
=400.67

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

PDL BioPharma's Inventory to Revenue for the quarter that ended in Jun. 2020 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Jun. 2020 ) / Revenue (Q: Jun. 2020 )
=11.5875 / 5.211
=2.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.


PDL BioPharma Inventory Turnover Related Terms

Thank you for viewing the detailed overview of PDL BioPharma's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


PDL BioPharma (PDL BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
932 Southwood Boulevard, Incline Villiage, NV, USA, 89451
PDL BioPharma Inc acquires and manages a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. The operating segments of the company are Medical Devices, Strategic Positions, Pharmaceutical and Income Generating Assets, of which key revenue is derived from the Pharmaceutical segment. The Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna and Tekturna HCT in the U.S, and Rasilez and Rasilez HCT in the rest of the world (collectively, the Noden Products). Geographically, the company operates in Europe, North America, Asia and Other countries, of which prime revenue is generated from Asia and North America.
Executives
David W Gryska director 749 N MARY AVE, SUNNYVALE CA 94085
John Peter Mclaughlin director C/O PDL BIOPHARMA, INC., 932 SOUTHWOOD BOULEVARD, INCLINE VILLAGE NV 89451
Dominique Monnet officer: President and CEO C/O ALEXION PHARMACEUTICALS, INC., 352 KNOTTER DRIVE, CHESHIRE CT 06410
Christopher Lewis Stone officer: VP, Gen. Counsel & Secretary 932 SOUTHWOOD BLVD. INCLINE VILLAGE NV 89451
Alan Lee Bazaar director 9 BEDFORD ROAD, KATONAH NY 10536
Natasha Hernday director 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Edward Imbrogno officer: VP Finance, CAO and Acting CFO 932 SOUTHWOOD BLVD. INCLINE VILLAGE NV 89451
Jill M. Jene officer: VP, Business Development 932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Harold E Selick director
Samuel R Saks director 3180 PORTER DRIVE, PALO ALTO CA 94304
Paul W Sandman director C/O PDL BIOPHARMA, INC., 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Shlomo Yanai director ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073
Peter S Garcia officer: Vice President, CFO ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Jody S Lindell director 2536 FILLMORE ST., SAN FRANCISCO CA 94115
Paul R Edick director C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010